ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Japan’s AGC invests in US, European biologics

by Michael McCoy
November 17, 2019 | APPEARED IN VOLUME 97, ISSUE 45

 

AGC will invest a total of almost $20 million in biologics contract manufacturing facilities in the US and Denmark. The Japanese firm will add a 500 L mammalian cell bioreactor in Seattle and a purification line in Copenhagen. The projects are set to be completed next year. AGC, the former Asahi Glass, got the facilities in 2017, when it bought the Danish firm CMC Biologics as part of a push into the life sciences.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment